Quoin Pharmaceuticals, Ltd. — Form 8-K
Filed August 14, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Quoin Pharmaceuticals (market cap ~$5.4M) announced FDA conditional approval of the brand name QYLEKI™ for QRX003 (Netherton Syndrome) on June 23, 2026; FDA clearance of first-ever IND for Peeling Skin Syndrome on July 9, 2026; U.S. patent allowance for combination Netherton treatment on June 30, 2026; and positive pediatric compassionate use data (June 16, 2026). Q2 net loss was $5.4M (vs. $3.7M prior year); six-month loss $10.4M (vs. $7.5M prior year). Cash position $10.8M as of June 30, 2026, sufficient to fund operations into 2027. Share count increased from 52.4M (Dec 2025) to 70.3M ordinary shares (June 2026).
Why this rating
Multiple regulatory milestones (brand approval, IND clearance, patent allowance) advance pipeline materially. For $5.4M market-cap biotech, $10.4M six-month burn and 34% share dilution are substantial; however, cash runway into 2027 and expanded indication portfolio (PSS first-ever formal trial) show meaningful progress offsetting burn.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.